How to read a Certificate of Analysis
Identity, purity, methods, specifications and batch matching—plus the separate questions behind HPLC, mass spectrometry, sterility and endotoxin results—what each field is there to tell you, and what it is not.
A Certificate of Analysis, or COA, is useful only when its reported material and batch can be connected to the product in front of the researcher. This guide covers reading a COA and the four kinds of evidence that most often sit behind it.
On this page
- Purity, identity and quantity
- Reading an HPLC report
- Mass spectrometry and identity
- Purity, sterility and endotoxin
Start with identity
Confirm the compound name, lot or batch number, testing laboratory, sample identifier, and report date. If the identifiers do not align, the result should not be assumed to describe the material.
Read the method beside the result
A purity percentage without a named analytical method and acceptance specification lacks essential context. Review what was tested, how it was tested, the stated result, and the release criterion together.
Keep claims batch-specific
One result should not automatically be generalized across unrelated inventory. Reforge’s intended framework places applicable documentation close to the corresponding released lot.
A report-reading example
Imagine a label marked lot A17 and a report marked sample B09. The compound names match, but the relationship between those identifiers is not explained. Record the mismatch and request the link between the sample and the supplied lot. Do not quietly treat matching product names as proof of a batch match.
“Not reported” is a useful conclusion. If a COA shows identity and chromatographic purity but no other testing, describe that exact scope. A clean layout, signature or high percentage does not fill in missing results.
Purity, identity and quantity
An identity result, a purity percentage and an amount measurement should not be treated as interchangeable. A peptide report can contain several reassuring numbers while still leaving an important question unanswered. Start by separating identity, purity and quantity instead of combining them into a single idea of “quality.”
Identity: what material was detected?
An identity test addresses whether the sample is consistent with the intended material under the method used. It should be read with the specification and any reference information. A product name printed above a result is not itself an analytical identity test.
Purity: what does the reported percentage describe?
A chromatographic percentage is tied to the method and reporting basis. Do not automatically interpret it as the fraction of the entire vial’s weight that is the intended peptide. Read the method, units and calculation description before translating the result into another claim.
Quantity: how much is present?
A nominal amount on a label and a measured amount on a report are different records. Ask what was actually measured and whether the basis is stated. ICH Q6A distinguishes identification, assay and impurity testing rather than treating them as one measurement.
Can one result answer all three?
Do not assume it can. Request an explanation from the laboratory or supplier when a report’s scope is unclear.
Reading an HPLC report
High-performance liquid chromatography, or HPLC, separates sample components under a defined method. In a peptide report, the chromatogram is part of the evidence behind the reported result. It deserves more attention than a percentage copied into a product image.
Read the method with the trace
Look for the sample identifier, method information, detector settings and peak table. Waters’ peptide application note illustrates how LC-UV impurity reporting depends on defined processing and acceptance criteria. Peak integration is a processing step, so it should not be treated as an explanation-free number.
What to ask about area percentage
Ask which peaks were included, how they were integrated and what the reported percentage represents. A chromatogram shows the response obtained under its conditions. It does not independently answer every question about identity, amount or contamination.
A report-review exercise
Suppose two reports show different purity percentages. Before calling one better, compare the sample identities, methods and reporting basis. If those differ or are missing, write “not directly comparable” in your notes and request clarification. Do not manufacture precision by subtracting percentages that represent different measurements.
The goal is an interpretable record. More decimal places, a clean-looking trace or a prominent main peak cannot replace the context needed to understand the measurement.
Mass spectrometry and peptide identity
Mass spectrometry analyzes ions by their mass-to-charge ratio. In peptide work, mass information and fragmentation data can support characterization. The precise conclusion depends on the experiment and interpretation, not simply the presence of “MS” on a certificate.
Mass measurement and sequence evidence
An intact-mass comparison and a sequencing workflow are different levels of information. Thermo Fisher’s overview describes peptide sequencing using liquid chromatography and mass spectrometry. When reviewing a report, ask whether it provides an expected-versus-observed mass comparison, fragmentation evidence or a more detailed sequence assignment.
Read the stated conclusion narrowly
If a report says a mass is consistent with the target, preserve that wording in your notes. Do not silently expand it into a claim that every structural feature, impurity or biological property has been confirmed.
Why combine different evidence?
A mass-related identity assessment and a chromatographic purity assessment can address different questions. Read them together, but retain their separate scope. Neither should be renamed a sterility or safety result. For example, a report with an expected-mass match but no quantity measurement should still leave quantity as an open question in a procurement worksheet. Ask for the missing information rather than guessing from a graph. Interpretation of the underlying spectrum belongs with qualified analytical personnel.
Purity, sterility and endotoxin
A chemical purity result should not be presented as evidence of sterility or an endotoxin result. A quality document is easiest to misread when different tests are bundled into one reassuring phrase. Chemical purity, sterility and bacterial endotoxin testing address different questions. A result in one category should not be copied into another.
Keep the test names visible
FDA guidance discusses bacterial endotoxin testing and method suitability separately from other product controls. FDA’s process-control guidance also treats sterility requirements as a distinct subject. These pharmaceutical references do not establish that any Reforge research product meets those standards.
What if only a purity report is available?
Describe only the evidence supplied. A document can be useful while remaining incomplete for a particular research requirement. The laboratory responsible for the study should decide what additional characterization is necessary. This guide does not provide contamination limits or make materials suitable for administration. Its purpose is to prevent a narrow analytical result from being turned into a broader claim that the report never made.
A review record to keep
A single worksheet covers all of the above. For each product and lot you evaluate, note:
- The product and lot being evaluated, and the record linking the sample to the supplied lot.
- The laboratory report identifier and date.
- A separate row for each property—identity, purity, quantity, and any sterility or endotoxin claim—with the test name, reported result and unit, the method, and any stated limit or acceptance criterion. For a mass result, record the expected and observed values where provided.
- The laboratory’s own interpretation and stated limitations.
- Where evidence is absent, “not reported” or “not provided” rather than an assumption; and, when two reports use different methods or sample identities, “not directly comparable” rather than a subtracted figure.
- Unanswered questions and the supplier’s response.
Leave a row blank when the evidence is absent. This practice is more informative than ranking materials by the largest percentage alone, and it does not establish a universal acceptance standard or certify a material’s suitability.
Questions to ask the supplier
- Which sample and lot does this report or trace represent, and does it apply to the supplied batch?
- What method and processing rules were applied?
- Which specific test supports each statement?
- Which figure is a measurement, and which is an acceptance limit? Are the result, units and limit stated?
- Is an independent identity result available?
- What limitations or sample-scope qualifications accompany it?
Related reading
Sources and scope
- FDA / ICH Q6A: specifications and acceptance criteria
- Waters: LC-UV synthetic peptide impurity reporting
- Thermo Fisher Scientific: peptide sequencing by mass spectrometry
- FDA: Pyrogen and Endotoxins Testing, Edition 2
- FDA: production and process controls questions and answers
Sources support the scientific or analytical concepts discussed. They do not certify Reforge products, establish their suitability for a particular study, or imply endorsement by the source organizations. Pharmaceutical guidance is cited for context, not as proof that a research material meets medicinal-product standards.
For laboratory research use only. Not for human or veterinary use.